相关实验视频

Updated: May 24, 2025

An Educational Video Demonstration of How to Prone a Critically Ill Intubated Patient
07:16

An Educational Video Demonstration of How to Prone a Critically Ill Intubated Patient

Published on: November 30, 2022

3.1K

在需要呼吸系统支持的住院COVID-19患者中服用更高剂量的皮质类固醇 (RECOVERY):一个随机,受控,开放标签,平台试验

    EClinicalMedicine
    |March 4, 2025
    PubMed
    概括

    高剂量的皮质类固醇并没有降低接受呼吸系统支持的住院COVID-19患者的死亡率. 在RECOVERY试验中,与通常护理相比,28天死亡率没有显著差异. 这表明更高的剂量对这个患者群体没有好处.

    关键词:
    在 COVID-19 疫情中,临床试验临床试验是指临床试验的临床试验.这是一种皮质类固醇.德克萨米他是一种死亡率 死亡率 死亡率

    更多相关视频

    Halogenated Agent Delivery in Porcine Model of Acute Respiratory Distress Syndrome via an Intensive Care Unit Type Device09:36

    Halogenated Agent Delivery in Porcine Model of Acute Respiratory Distress Syndrome via an Intensive Care Unit Type Device

    Published on: September 24, 2020

    2.7K
    In Vitro Method to Control Concentrations of Halogenated Gases in Cultured Alveolar Epithelial Cells04:56

    In Vitro Method to Control Concentrations of Halogenated Gases in Cultured Alveolar Epithelial Cells

    Published on: October 23, 2018

    6.5K

    相关概念视频

    COPD: Management Using Bronchodilators and Corticosteroids01:26

    COPD: Management Using Bronchodilators and Corticosteroids

    Chronic obstructive pulmonary isease (COPD) involves a group of progressive lung disorders characterized by persistent airflow limitation and chronic respiratory symptoms. Asthma-COPD Overlap Syndrome (ACOS), encompassing features of both asthma and Chronic obstructive pulmonary disease (COPD), is a group of progressive lung disorders that includes chronic bronchitis, emphysema, and refractory (non-reversible) asthma. ACOS leads to complex clinical presentations that combine the inflammatory...
    170
    Antiasthma Drugs: Inhaled Corticosteroids and Glucocorticoids01:25

    Antiasthma Drugs: Inhaled Corticosteroids and Glucocorticoids

    Inhaled corticosteroids (ICS) are anti-inflammatory drugs used primarily in treating persistent asthma and providing long-term maintenance. They target the bronchial mucosa, the lining of the airways, to control inflammation, a critical factor in asthma progression and exacerbation.
    ICS work through a multifaceted mechanism of action. They suppress the inflammatory response caused by the proliferation of TH cells. They also reduce the transcription of the IL-2 gene, which is involved in the...
    201
    Acute Respiratory Failure-V01:29

    Acute Respiratory Failure-V

    The treatment for acute respiratory failure varies based on factors like the underlying cause, overall health, and severity. A collaborative healthcare team is essential for early detection, often through arterial blood gas analysis. Identifying the cause is the primary goal, with treatment strategies adjusted for ventilation/perfusion (V/Q) mismatch, shunting, or diffusion impairment.
    Ensure that patients are monitored continuously for their response to therapy, including changes in...
    113
    Pulmonary Tuberculosis I01:29

    Pulmonary Tuberculosis I

    Tuberculosis, often called TB, is a contagious illness primarily caused by Mycobacterium tuberculosis. It mainly affects the lung parenchyma but can also impact other body parts.
    Causative Organism
    The primary infectious agent causing tuberculosis is Mycobacterium tuberculosis, a slow-growing, acid-fast, aerobic rod that exhibits sensitivity to heat and ultraviolet light. Instances of Mycobacterium bovis and Mycobacterium avium contributing to the development of TB infection are rare.
    Mode of...
    215
    Pneumonia IV: Management01:28

    Pneumonia IV: Management

    The treatment of pneumonia varies based on its severity and the causative pathogen. Here is a structured approach to managing pneumonia, integrating pharmaceutical and supportive care strategies.
    Bacterial Pneumonia Treatment
    For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
    286
    Acute Respiratory Failure-II01:21

    Acute Respiratory Failure-II

    Type I Respiratory Failure, or hypoxemic respiratory failure, occurs when the partial pressure of oxygen (PaO2) in arterial blood falls below 60 mmHg while breathing room air without a corresponding increase in arterial carbon dioxide levels (PaCO2). This condition highlights a significant impairment in the lungs' capacity to oxygenate the blood.
    The underlying physiological abnormalities that contribute to hypoxemic respiratory failure include:
    158